Scholarlink

Background and objective <p>Cancer-associated fibroblasts (CAFs), critical constituents of the tumor microenvironment, promote tumor progression and therapeutic resistance through exosome secretion. However, the mechanisms by which CAF-derived exosomes contribute to trastuzumab resistance in HER2-positive breast cancer remain unclear. This study investigated whether CAF-derived exosomes activate the YAP-USP8 axis to stabilize HER2 and induce trastuzumab resistance.</p> Methods <p>Primary CAFs and normal fibroblasts (NFs) were isolated from HER2-positive breast cancer specimens, and exosomes were characterized by TEM, nanoparticle tracking analysis, and immunoblotting of exosomal markers. HER2-positive breast cancer cells (HCC1954 and BT-474) were treated with CAF- or NF-derived exosomes in vitro. Mechanistic studies were performed mainly in HCC1954 cells, whereas BT-474 cells were used for validation. Cargo dependency was assessed using RNase/Proteinase K protection assays, and YAP pathway involvement was examined using Verteporfin. In vivo tumor growth was evaluated using xenograft models.</p> Results <p>CAF-derived exosomes reduced LATS1 and YAP phosphorylation (<i>p</i> &lt; 0.001), enhanced nuclear YAP accumulation, and upregulated USP8 transcription, leading to HER2 stabilization (<i>P</i> &lt; 0.001). Membrane disruption abolished Hippo suppression, indicating dependence on intravesicular cargo. CAF-exo treatment increased proliferation, elevated trastuzumab IC<sub>50</sub>, reduced apoptosis, and accelerated tumor growth in vivo (all <i>p</i> &lt; 0.001). These effects were reproduced in BT-474 cells and were reversed by YAP or USP8 silencing. Pharmacological inhibition of YAP similarly restored trastuzumab sensitivity. TCGA-BRCA analysis revealed positive correlations between YAP1 and USP8, and between USP8 and ERBB2, supporting the molecular relevance of this axis.</p> Conclusion <p>This study identified a novel CAF-exosome-YAP-USP8-HER2 signaling axis that drives trastuzumab insensitivity in HER2-positive breast cancer. Intervening in this pathway may represent a potential treatment approach to counteract microenvironment-induced chemoresistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Weijia Yu,
  • Li Jiang

摘要

Background and objective

Cancer-associated fibroblasts (CAFs), critical constituents of the tumor microenvironment, promote tumor progression and therapeutic resistance through exosome secretion. However, the mechanisms by which CAF-derived exosomes contribute to trastuzumab resistance in HER2-positive breast cancer remain unclear. This study investigated whether CAF-derived exosomes activate the YAP-USP8 axis to stabilize HER2 and induce trastuzumab resistance.

Methods

Primary CAFs and normal fibroblasts (NFs) were isolated from HER2-positive breast cancer specimens, and exosomes were characterized by TEM, nanoparticle tracking analysis, and immunoblotting of exosomal markers. HER2-positive breast cancer cells (HCC1954 and BT-474) were treated with CAF- or NF-derived exosomes in vitro. Mechanistic studies were performed mainly in HCC1954 cells, whereas BT-474 cells were used for validation. Cargo dependency was assessed using RNase/Proteinase K protection assays, and YAP pathway involvement was examined using Verteporfin. In vivo tumor growth was evaluated using xenograft models.

Results

CAF-derived exosomes reduced LATS1 and YAP phosphorylation (p < 0.001), enhanced nuclear YAP accumulation, and upregulated USP8 transcription, leading to HER2 stabilization (P < 0.001). Membrane disruption abolished Hippo suppression, indicating dependence on intravesicular cargo. CAF-exo treatment increased proliferation, elevated trastuzumab IC50, reduced apoptosis, and accelerated tumor growth in vivo (all p < 0.001). These effects were reproduced in BT-474 cells and were reversed by YAP or USP8 silencing. Pharmacological inhibition of YAP similarly restored trastuzumab sensitivity. TCGA-BRCA analysis revealed positive correlations between YAP1 and USP8, and between USP8 and ERBB2, supporting the molecular relevance of this axis.

Conclusion

This study identified a novel CAF-exosome-YAP-USP8-HER2 signaling axis that drives trastuzumab insensitivity in HER2-positive breast cancer. Intervening in this pathway may represent a potential treatment approach to counteract microenvironment-induced chemoresistance.